Prediman K. Shah
Division of Cardiology and Oppenheimer Atherosclerosis Research Center
Cedars Sinai Heart Institute
Suite 5531
Cedars Sinai Medical Center
USA
Name/email consistency: high
- Atherosclerosis: targeting endogenous apo A-I--a new approach for raising HDL. Shah, P.K. Nat. Rev. Cardiol (2011)
- Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Shah, P.K. Curr. Opin. Cardiol. (2010)
- The SHAPE paradigm: a commentary. Shah, P.K. Circ. Cardiovasc. Qual. Outcomes (2010)
- Inflammation and plaque vulnerability. Shah, P.K. Cardiovasc. Drugs. Ther (2009)
- Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach. Shah, P.K. Curr. Pharm. Des. (2007)
- Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Shah, P.K. Eur. Heart J. (2007)
- Emerging HDL-based Therapies for Atherothrombotic Vascular Disease. Shah, P.K. Curr. Treat. Options. Cardiovasc. Med (2007)
- Molecular mechanisms of plaque instability. Shah, P.K. Curr. Opin. Lipidol. (2007)
- Insights into the molecular mechanisms of plaque rupture and thrombosis. Shah, P.K. Indian. Heart. J (2005)
- Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Shah, P.K., Chyu, K.Y. Trends Cardiovasc. Med. (2005)
- Immunomodulation of atherosclerosis with a vaccine. Shah, P.K., Chyu, K.Y., Fredrikson, G.N., Nilsson, J. Nature Clinical Practice. Cardiovascular Medicine (2005)
- Vaccination for atherosclerosis: a novel therapeutic paradigm. Shah, P.K., Chyu, K.Y., Fredrikson, G.N., Nilsson, J. Expert. Rev. Vaccines (2004)
- Mechanisms of plaque vulnerability and rupture. Shah, P.K. J. Am. Coll. Cardiol. (2003)
- Myocardial infarction and ischemia. Shah, P.K. J. Am. Coll. Cardiol. (2003)
- Pathophysiology of plaque rupture and the concept of plaque stabilization. Shah, P.K. Cardiol. Clin (2003)
- Chronic infections and atherosclerosis/thrombosis. Shah, P.K. Curr. Atheroscler. Rep (2002)
- High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Shah, P.K., Yano, J., Reyes, O., Chyu, K.Y., Kaul, S., Bisgaier, C.L., Drake, S., Cercek, B. Circulation (2001)
- Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Shah, P.K., Kaul, S., Nilsson, J., Cercek, B. Circulation (2001)
- Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Shah, P.K., Kaul, S., Nilsson, J., Cercek, B. Circulation (2001)
- Focus on HDL: a new treatment paradigm for athero-thrombotic vascular disease. Shah, P.K. Expert. Opin. Investig. Drugs (2000)
- Plaque disruption and thrombosis. Potential role of inflammation and infection. Shah, P.K. Cardiol. Clin (1999)